Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey… - … England Journal of …, 2012 - Mass Medical Soc
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …
[HTML][HTML] Targeted therapy in melanoma–the role of BRAF, RAS and KIT mutations
SM Goldinger, C Murer, P Stieger, R Dummer - European Journal of Cancer …, 2013 - Elsevier
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by
clinical and molecular features, including targetable mutations in several kinases such as …
clinical and molecular features, including targetable mutations in several kinases such as …
Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies
Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
An acquired vulnerability of drug-resistant melanoma with therapeutic potential
L Wang, RL de Oliveira, S Huijberts, E Bosdriesz… - Cell, 2018 - cell.com
Summary BRAF (V600E) mutant melanomas treated with inhibitors of the BRAF and MEK
kinases almost invariably develop resistance that is frequently caused by reactivation of the …
kinases almost invariably develop resistance that is frequently caused by reactivation of the …
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm …
M Schreuer, Y Jansen, S Planken, I Chevolet… - The Lancet …, 2017 - thelancet.com
Summary Background Patients with BRAF V600-mutant melanoma benefit from treatment
with the combination of BRAF and MEK inhibitors, but resistance and disease progression …
with the combination of BRAF and MEK inhibitors, but resistance and disease progression …
Chemotherapy in the management of advanced cutaneous malignant melanoma
JJ Luke, GK Schwartz - Clinics in dermatology, 2013 - Elsevier
The recent past has witnessed unprecedented clinical progress in the treatment of advanced
malignant melanoma through targeting of mutant BRAF in approximately 50% of patients …
malignant melanoma through targeting of mutant BRAF in approximately 50% of patients …
Immunological effects of BRAF+ MEK inhibition
PA Ascierto, R Dummer - Oncoimmunology, 2018 - Taylor & Francis
Recent developments in immunotherapy have prolonged overall survival in metastatic
melanoma with the possibility to reach a long-term benefit. Targeted therapies based on …
melanoma with the possibility to reach a long-term benefit. Targeted therapies based on …
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells
Combination therapy with BRAF and MEK inhibition is currently in clinical development for
the treatment of BRAF-mutated malignant melanoma. BRAF inhibitors are associated with …
the treatment of BRAF-mutated malignant melanoma. BRAF inhibitors are associated with …
Targeting BRAF in melanoma: biological and clinical challenges
M Mandalà, C Voit - Critical reviews in oncology/hematology, 2013 - Elsevier
Melanoma is an aggressive form of skin cancer that causes the greatest number of skin
cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by …
cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by …